N-(1-methyl-6-oxo-1,6-dihydro-pyrimidin-4-yl)-acetamide | 102169-46-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-(1-methyl-6-oxo-1,6-dihydro-pyrimidin-4-yl)-acetamide
• 英文别名: N-(1-Methyl-6-oxo-1,6-dihydro-pyrimidin-4-yl)-acetamid；N-(1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)acetamide；N-(1-methyl-6-oxopyrimidin-4-yl)acetamide
• CAS: 102169-46-0
• 化学式: C₇H₉N₃O₂
• mdl: MFCD02091083
• 分子量: 167.167
• InChiKey: BJBFVPDEDOMXLC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  61.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  6-氨基-2-甲基硫代-3-甲基尿嘧啶 在 水 、 镍 作用下， 生成 N-(1-methyl-6-oxo-1,6-dihydro-pyrimidin-4-yl)-acetamide
  参考文献：
  名称：

  Pfleiderer; Liedek, Justus Liebigs Annalen der Chemie, 1958, vol. 612, p. 163,164

  摘要：

  DOI：

文献信息

• SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS
  申请人：GlaxoSmithKline Intellectual Property (No.2) Limited

  公开号：US20170355705A1

  公开（公告）日：2017-12-14

  The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and for use in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.
• Pfleiderer; Liedek, Justus Liebigs Annalen der Chemie, 1958, vol. 612, p. 163,164
  作者：Pfleiderer、Liedek

  DOI：——

  日期：——